FDA Hands Lannett Goal Date On Generic Advair
Lannett: Anticipate More Than One Review Cycle
Executive Summary
Lannett continues to eye the potential launch of its partnered Advair generic next year, after the lucrative respiratory asset was accepted for filing by the FDA.
You may also be interested in...
Lannett New York Listing Under Threat As FDA Says No On Advair
A strained balance sheet and share price has led the New York Stock Exchange to write to Lannett about its future listing, adding to its woes as the FDA confirmed it was not currently in a position to approve its partnered generic Advair Diskus asset.
Lannett: Pricing Pressure ‘Intensified Beyond Historical Norms’
Not many firms report a negative EBITDA when adjusted for costs, but this Lannett's fate during its FY2022 Q2. Management addressed challenges for Lannett’s base business and the ways in which it intends to turn the tide in the coming years.
Lannett: Pricing Pressure Has ‘Intensified Beyond Historical Norms’
Not many firms report a negative EBITDA when adjusted for costs, but this was the fate of Lannett during its financial Q2. Management addressed the challenges for Lannett’s base business and the ways in which the firm intends to turn the tide in the coming years.